 NEW YORK, Aug. 2, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoths HT-ALZ in an animal model. The goal of the study is to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimers disease and to determine if HT-ALZ can improve learning and memory in an animal model of Alzheimers disease. 